Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: stalk (11), shoot (23), trunk (4), twig (1), branch (22), stop (1000)

Religious influences in medical decisions made for children

Description: Mr Wheeler considers whether the religious beliefs of parents should affect decisions made about children's medical care.
Url: /HealthProfessionals/Clinical-law-updates/Religious-influences-in-medical-decisions-made-for-children.aspx

Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications

Description: Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications ? ? ? ? Background Scope: who this policy and guidance applies
Url: /Media/Southampton-Clinical-Research/Downloads/Joint-Partnership-Policy-and-Guidance-on-Pre-clinical-and-Clinical-Research-Publications.pdf

People who refuse medical or surgical treatment for self inflicted injury

Description: Auto Generated Title On these pages I discuss the clinical law on which our nursing and medical staff rely when caring for our patients. M
Url: /HealthProfessionals/Clinical-law-updates/People-who-refuse-medical-or-surgical-treatment-for-self-inflicted-injury.aspx

Inotuzumab Ozogamicin

Description: Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description: Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone (20) Indication  C
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab

Description: Chemotherapy Protocol LYMPHOMA CISPLATIN-DEXAMETHASONE-GEMCITABINE-RITUXIMAB (RGDP) Regimen • Lymphoma – RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab Indication • Pat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or re
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an op
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

MyelomaVTDBortezomib(SC)DexamethasoneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD (SC-28)-BORTEZOMIB (SC)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (28)-Bortezomib (SC)-Dexamethasone-Thalidomide (28 day) Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibSCDexamethasoneThalidomideVer1.pdf

MyelomaVTDBortezomib(IV)DexamethasoneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA VTD (IV-28)-BORTEZOMIB (IV)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (IV-28)-Bortezomib (IV)-Dexamethasone-Thalidomide (28 day) In
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibIVDexamethasoneThalidomideVer1.pdf

61 to 70 of 89

Previous … 5 6 7 8 9 Next